Does Express Scripts Cover Weight-Loss Drugs? (2026)

Short version: Express Scripts is a pharmacy benefit manager (PBM), not an insurer. It is owned by Cigna and sits, with Cigna's specialty pharmacy Accredo, under the Evernorth umbrella. Express Scripts does not decide on its own whether you get a weight-loss drug — it administers the formulary, prior authorization, and step therapy that your plan sponsor (usually your employer) selected. Weight-loss GLP-1s — Wegovy, Zepbound, and Saxenda — are excluded from the standard Express Scripts National Preferred Formulary as anti-obesity medications, and are covered only when an employer specifically buys anti-obesity-medication (AOM) coverage.^[1][2] GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus) are widely covered with prior authorization.^[3] Express Scripts has built two affordability programs on top of this: the Evernorth $200/month benefit option and an expanded Patient Assurance Program.^[4][5] Medicare Part D cannot cover weight-loss-only GLP-1s by federal statute — but the new Medicare GLP-1 Bridge demonstration (July 1, 2026) and the Zepbound-OSA / Wegovy-CV carve-ins change that picture.^[6][7]

At a glance

• Express Scripts is a PBM, not an insurer. It is owned by Cigna and operates, alongside Accredo and EnGuide home delivery, under the Evernorth umbrella. It administers the formulary, PA, and step therapy your plan sponsor chose — it does not set coverage on its own.^[1]
• Weight-loss GLP-1s are excluded from the standard formulary. Wegovy, Zepbound, and Saxenda are excluded from the 2026 Express Scripts National Preferred Formulary as anti-obesity medications.^[2] Coverage exists only when an employer plan sponsor buys AOM coverage as an add-on.^[1]
• Diabetes GLP-1s are widely covered with PA. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus are generally on-formulary for the type 2 diabetes indication with prior authorization.^[3]
• Plan sponsors opt in or out. Since 2024, Express Scripts has let plan sponsors choose to add Saxenda, Wegovy, and Zepbound for weight loss — or to exclude them entirely.^[1] Two members with identical diagnoses can get opposite answers based purely on employer plan design.
• Evernorth $200/month cap: for participating employer plans, Evernorth caps member out-of-pocket on Wegovy and Zepbound at $200/month (launched May 21, 2025), and the amount counts toward the annual deductible.^[4] It sits inside the EncircleRx weight-management program (more than 9 million enrolled lives).^[4]
• Patient Assurance Program: Express Scripts' long-running copay-cap program (historically $25 per 34-day supply / $75 per 90-day supply for diabetes/cardiovascular drugs) expanded to add weight-loss GLP-1s in 2025.^[5]
• Medicare Part D: NO for weight-loss-only Wegovy/Zepbound/Saxenda under Social Security Act §1860D-2(e)(2)(A).^[6] YES for Zepbound OSA and Wegovy cardiovascular risk reduction.^[8][9] The new Medicare GLP-1 Bridge adds a $50/month weight-management path from July 1, 2026.^[7]

Express Scripts is a PBM, not an insurer — why that matters

The single most common misconception is that Express Scripts “decides” whether your weight-loss drug is covered. It does not. Express Scripts is a pharmacy benefit manager — the company that runs the prescription-drug side of a health plan on behalf of the entity that pays the bills. That paying entity is the plan sponsor: usually your employer (for commercial coverage), or an insurer or government program. Express Scripts is owned by Cigna, and together with Cigna's specialty pharmacy Accredo and the EnGuide home-delivery pharmacy, it operates under the Evernorth health-services brand.^[1]

What Express Scripts controls, on the plan sponsor's behalf, is the machinery: the formulary (which drugs are covered and on which tier), prior-authorization adjudication, and step-therapy and quantity-limit rules. What it does not control is whether weight-loss-drug coverage exists in the first place — that is a plan-sponsor benefit-design decision.^[1]

So the practical question is never just “does Express Scripts cover Wegovy.” It is “did my plan sponsor add anti-obesity-medication coverage to its Express Scripts plan, and which formulary did they choose?” Three formulary paths matter:

• Express Scripts National Preferred Formulary (NPF) — the standard book of business. Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) are excluded from the base NPF as anti-obesity medications.^[2] Diabetes GLP-1s remain covered.^[3]
• Custom employer formularies with an AOM benefit. Plan sponsors can buy weight-loss-drug coverage as an add-on; many run through Evernorth's weight-management benefit option that caps member cost at $200/month.^[4]
• Accredo / EnGuide fulfillment. Some plans route GLP-1 fills and PA paperwork through Evernorth's specialty pharmacy (Accredo) or the EnGuide home-delivery pharmacy rather than retail.^[4]

Weight-loss GLP-1s are excluded from the standard National Preferred Formulary

The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg) — are excluded from the base 2026 Express Scripts National Preferred Formulary, where they are listed among excluded weight-loss medications.^[2] That exclusion is the default. It does not mean a member can never get them; it means the drug is not covered unless the plan sponsor specifically buys AOM coverage.

Since 2024, Express Scripts has explicitly let plan sponsors opt to cover Saxenda, Wegovy, and Zepbound for weight loss — or to keep them excluded. This plan-sponsor choice is why coverage is so inconsistent: a large employer that prioritizes obesity care may add the AOM benefit, while a cost-sensitive employer in the same industry excludes it outright.^[1]

When a plan does include AOM coverage, weight-loss GLP-1s are typically placed on a non-preferred brand tier and gated behind prior authorization. Real-world Express Scripts PA criteria for a weight-management GLP-1 generally require, with documentation: age 18 or older; a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity (such as type 2 diabetes, hypertension, or dyslipidemia); often a documented trial of lower-cost weight-management drugs; participation in a comprehensive weight-management program; and a preferred-product step-therapy requirement, plus quantity limits. Exact thresholds vary by the plan's chosen policy.^[3] For the underlying weight-loss magnitudes that anchor those PA thresholds, compare provider options on our best semaglutide providers page.

GLP-1 coverage for type 2 diabetes (widely covered)

On Express Scripts commercial plans, GLP-1 receptor agonists for the type 2 diabetes indication are generally on-formulary with prior authorization. Commonly covered agents:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with branded and authorized-generic forms.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.

Typical Express Scripts PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Critically, the diabetes indication is not subject to the AOM-exclusion problem, because the drug is being used for diabetes, not weight loss.^[3] For drug-level detail, see our semaglutide drug page and tirzepatide drug page.

The Evernorth $200/month cap and EncircleRx

On May 21, 2025, Evernorth launched a benefit option that caps member out-of-pocket cost for Wegovy and Zepbound at $200 per month for participating employer plans — with the added feature that the amount counts toward the member's annual deductible. The company says members can save up to roughly $3,600 a year versus buying the drugs directly from manufacturers. The program is built on direct negotiations with the manufacturers; fills route through a broad retail network or Evernorth's EnGuide home-delivery pharmacy (staffed by clinicians with GLP-1 expertise), with a simplified, automated prior-authorization step.^[4]

This sits inside Evernorth's broader EncircleRx weight-management program, a financial model that the company reports has grown to more than 9 million enrolled lives and saved health plans more than $200 million since its 2024 launch. EncircleRx is positioned as a financial-guardrail plus clinical-oversight wrapper around GLP-1 access; participating plans receive deeper per-prescription discounts.^[4] Two caveats for members:

• The cap is a plan-sponsor option, not a default. Your employer must have selected the weight-management benefit option for you to get the $200 ceiling. If they did not buy AOM coverage at all, there is no cap because there is no coverage.^[4]
• The cap does not remove the PA gate. You still have to clear the BMI, comorbidity, weight-program, and step-therapy requirements before the $200 cap applies.^[3]

The Patient Assurance Program

Separately, Express Scripts runs a long-standing Patient Assurance Program that caps out-of-pocket cost on select brand-name single-source drugs to improve adherence. Historically it covered insulin and other diabetes and cardiovascular therapies at $25 for up to a 34-day supply or $75 for a 90-day supply for eligible members on participating plans. In 2025, Express Scripts expanded the program to add weight-loss GLP-1s (Wegovy and Zepbound) and to return diabetes GLP-1s such as Ozempic and Rybelsus.^[5]

As with the $200 cap, the Patient Assurance Program only helps if (a) your plan sponsor participates and (b) the weight-loss drug is actually covered under your plan in the first place. It is an affordability layer on top of coverage, not a substitute for it.^[5]

Express Scripts Medicare — federal Part D exclusion (and the new exceptions)

Express Scripts administers Part D benefits for many Medicare plans. Like every Medicare Part D plan in the country, those plans operate under Social Security Act §1860D-2(e)(2)(A), which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[6] This is a federal statutory exclusion — no Part D plan can cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications, no matter how much medical necessity is documented.

Three pathways let a Medicare member access an otherwise-excluded GLP-1:

• Ozempic / Mounjaro / Trulicity for T2D. Type 2 diabetes is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.^[6]
• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024; because OSA is not weight loss, the Part D exclusion does not block coverage. The SURMOUNT-OSA trial is the underlying evidence base.^[8]
• Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication (March 2024) is reducing major adverse cardiovascular events in adults with established CVD and overweight/obesity. As a non-weight-loss indication, this is coverable on Part D, though formulary placement and PA vary by plan.^[9]

The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027)

A major 2026 development for Medicare members on Express Scripts-administered Part D plans: CMS launched the Medicare GLP-1 Bridge, a time-limited demonstration that lets eligible Part D beneficiaries get certain GLP-1 drugs for weight management at a flat $50/month copay, running July 1, 2026 through December 31, 2027.^[7] Key mechanics:

• $50 flat copay regardless of Part D benefit phase. The $50 does not count toward the Part D deductible or the annual out-of-pocket maximum.^[7]
• Part D plans do not have to opt in. Beneficiaries can access an eligible GLP-1 even if their Part D plan does not participate, and sponsors carry no risk for the drug under the demonstration.^[7]
• Clinical eligibility is gated on BMI thresholds plus qualifying conditions; a provider must submit a PA and a prescription for an eligible weight-management use.^[7]
• No member action required to be eligible — beneficiaries do not have to register or opt in.^[7]

How to find out if YOUR plan covers Wegovy or Zepbound through Express Scripts

Four reliable ways, in order from fastest to most authoritative:

1. express-scripts.com drug-coverage search. Sign in with your plan, search “Wegovy” or “Zepbound,” and the result indicates tier, PA status, step therapy, and quantity limits for your specific formulary. This is the canonical source for your plan.^[1]
2. Phone Express Scripts member services. The number is on the back of your card. Ask specifically: “Does my plan include anti-obesity-medication coverage? Is Wegovy/Zepbound covered for weight loss, what tier, and what are the PA and step-therapy requirements?”
3. Ask HR or your benefits administrator whether AOM coverage was purchased. Because weight-loss-drug coverage is a plan-sponsor add-on, HR can confirm whether your group bought it — and whether you are on the Evernorth $200-cap option or the Patient Assurance Program.^[4][5]
4. Request the Summary Plan Description (SPD) / Evidence of Coverage (EOC). AOM exclusions, if present, are listed in the excluded-benefits section. For Medicare plans, check the EOC and the formulary's excluded-drugs list.

Prior authorization and appeal pathway (through Express Scripts)

Because the benefit runs through Express Scripts as PBM, the PA and appeal machinery is the PBM's. The typical flow:

1. Your prescriber submits a prior-authorization request to Express Scripts (often via the Express Scripts/CoverMyMeds electronic PA portal) documenting BMI, comorbidities, any required prior drug trials, and weight-management-program enrollment.^[3]
2. Express Scripts adjudicates against the plan's coverage policy; specialty fills may route through Accredo or EnGuide home delivery. Standard PA decisions are typically returned within a few business days; expedited review is available for urgent cases.^[4]
3. If denied, a first-level internal appeal is filed within the timeframe on the denial notice; the prescriber can add clinical documentation or a step-therapy exception request.
4. If upheld, a second-level internal appeal follows, then an external review by an independent review organization. For fully-insured plans the external review routes through the state insurance regulator; for ERISA self-funded employer plans it follows the federal ERISA framework and ultimately the U.S. Department of Labor.

For the operational playbook on appealing dropped coverage across any payer, see our GLP-1 insurance dropped-coverage appeal playbook . For side effects to document during an appeal, see our GLP-1 side-effect questions hub .

If your plan denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Check the Medicare GLP-1 Bridge (Medicare members). Starting July 1, 2026, eligible Part D members can get a covered GLP-1 for weight management at $50/month even if their plan does not participate.^[7]
• The Zepbound OSA pathway (Medicare or commercial). With a moderate-to-severe OSA diagnosis (AHI ≥ 15 on polysomnography), your prescriber can submit a Zepbound PA for the OSA indication rather than weight loss — the Part D exclusion does not apply.^[8]
• Wegovy for cardiovascular risk reduction. With established CVD plus overweight/obesity, your prescriber can submit a Wegovy PA for the CV-risk-reduction indication — a non-weight-loss indication.^[9]
• Cash-pay routes. LillyDirect Self Pay vials run roughly $299–$699/month by dose; compounded tirzepatide/semaglutide via verified 503A telehealth is another lower-cost route, though it is not brand Wegovy/Zepbound and quality varies.
• Push HR at open enrollment, or compare another payer. Because AOM coverage is a plan-sponsor decision, the realistic lever is asking HR to add the Evernorth weight-management benefit. To see how other payers handle this, compare our Cigna weight-loss coverage review , Aetna review , and Kaiser Permanente review .

Verdict — what most Express Scripts members should expect

For the median member asking does Express Scripts cover weight-loss drugs: the answer is not a single national yes-or-no, because Express Scripts is a PBM that executes your plan sponsor's benefit design.

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES with Express Scripts prior authorization confirming the T2D diagnosis.^[3]
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): excluded from the standard Express Scripts National Preferred Formulary — covered ONLY if your plan sponsor bought AOM coverage, and then only after a strict PA gate.^[1][2]
3. Medicare members: NO for weight-loss-only; YES for Zepbound OSA and Wegovy CV-risk-reduction; and the Medicare GLP-1 Bridge gives eligible members a $50/month weight-management path from July 1, 2026.^[7]
4. If covered: the Evernorth $200/month cap (when the plan sponsor selects it) is the cheapest commercial path, with the amount counting toward the deductible; the Patient Assurance Program is a second affordability layer.^[4][5]

The headline caveat: because AOM coverage is a discretionary, revisable plan-sponsor benefit, the same employer can add it one year and drop it the next. The single most reliable thing you can do is sign in to express-scripts.com under your specific plan and run the drug-coverage search — and ask HR whether the weight-management benefit was purchased.

Further reading

• Does Cigna cover weight loss drugs?
• Does Aetna cover weight loss drugs?
• Does Kaiser Permanente cover weight loss drugs?